Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brain-Computer Interface Device Makers Must Consider Accessibility And Deployability

This article was originally published in The Gray Sheet

Executive Summary

Brain-computer interface device makers should consider customer accessibility and clinicians’ ability to deploy the BCI system to get to market, Medtronic technology director says at an FDA meeting. New brain-machine interface include products to help paraplegics walk and people with tremors to grasp tools used in daily life.

You may also be interested in...



Thought-Controlled Prosthetics Get US FDA 'Leapfrog' Treatment

A new "leapfrog" draft guidance from the US agency addresses implanted brain-computer interface prosthetic devices, and, specifically, the information sponsors should be prepared to submit for pre-submissions meetings and investigational device exemptions.

FDA Seeks Feedback On Brain-Computer Interface Devices For Amputees

The agency has scheduled a November workshop on brain-computer interface devices to discuss scientific, clinical and regulatory considerations for firms designing neuroprostheses that work with the central nervous system to help restore motor capabilities in paralyzed and amputee patients. The meeting could inform development of a draft guidance.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel